Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene

Cancer Control. 2009 Jan;16(1):66-9. doi: 10.1177/107327480901600110.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma, Papillary / drug therapy
  • Anticarcinogenic Agents / administration & dosage*
  • Anticarcinogenic Agents / adverse effects
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Benzenesulfonates / administration & dosage
  • Benzenesulfonates / adverse effects*
  • Bexarotene
  • Carboplatin / administration & dosage
  • Clinical Trials as Topic
  • Cystadenocarcinoma, Serous / drug therapy
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Hypertriglyceridemia / chemically induced
  • Hypothyroidism / chemically induced
  • Keratoacanthoma / chemically induced
  • Keratoacanthoma / pathology
  • Keratoacanthoma / prevention & control*
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Niacinamide / analogs & derivatives
  • Ovarian Neoplasms / drug therapy
  • Paclitaxel / administration & dosage
  • Phenylurea Compounds
  • Pyridines / administration & dosage
  • Pyridines / adverse effects*
  • Skin Diseases / chemically induced
  • Skin Diseases / pathology
  • Skin Diseases / prevention & control*
  • Sorafenib
  • Tetrahydronaphthalenes / administration & dosage*
  • Tetrahydronaphthalenes / adverse effects

Substances

  • Anticarcinogenic Agents
  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Tetrahydronaphthalenes
  • Niacinamide
  • Sorafenib
  • Bexarotene
  • Carboplatin
  • Paclitaxel